Last reviewed · How we verify
Furosemide and matched saline hydration
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting fluid excretion, while saline hydration provides intravenous fluid replacement to maintain hemodynamic stability.
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting fluid excretion, while saline hydration provides intravenous fluid replacement to maintain hemodynamic stability. Used for Acute decompensated heart failure with fluid overload, Cardiorenal syndrome prevention during diuresis.
At a glance
| Generic name | Furosemide and matched saline hydration |
|---|---|
| Sponsor | Centro Cardiologico Monzino |
| Drug class | Loop diuretic with intravenous fluid replacement |
| Target | Na-K-2Cl cotransporter (NKCC2) in the loop of Henle |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This combination therapy uses furosemide to reduce excess fluid volume and congestion, particularly in heart failure or acute decompensated states, while matched saline hydration simultaneously replaces intravascular volume to prevent hypotension and preserve renal perfusion. The strategy aims to achieve decongestion without inducing cardiorenal syndrome or worsening renal function, a concept sometimes referred to as 'diuresis with matched hydration' in cardiology.
Approved indications
- Acute decompensated heart failure with fluid overload
- Cardiorenal syndrome prevention during diuresis
Common side effects
- Hypokalemia
- Hyponatremia
- Acute kidney injury
- Hypotension
- Hyperuricemia
Key clinical trials
- RenalGuard System and Contrast Media (PHASE3)
- Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: